1. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.
- Author
-
Zhang XM, Li YX, Wang WH, Jin J, Wang SL, Liu YP, Song YW, Ren H, Fang H, Zhou LQ, Chen B, Qi SN, Liu QF, Lu NN, Liu XF, and Yu ZH
- Subjects
- Adolescent, Adult, Aged, Cyclophosphamide therapeutic use, Female, Gamma Rays, Humans, Lymph Nodes pathology, Lymph Nodes radiation effects, Lymphoma, Large-Cell, Anaplastic mortality, Lymphoma, Large-Cell, Anaplastic pathology, Lymphoma, Large-Cell, Anaplastic radiotherapy, Male, Middle Aged, Neoplasm Staging, Prednisone therapeutic use, Prognosis, Recurrence, Survival Rate, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin therapeutic use, Lymph Nodes drug effects, Lymphoma, Large-Cell, Anaplastic drug therapy
- Abstract
The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large-cell lymphoma (ALCL) treated with doxorubicin-based chemotherapy and radiotherapy. Forty-six adult patients with early stage systemic ALCL received chemotherapy followed by radiotherapy. All patients except two received chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen. Twenty patients had stage I disease, and 26 patients had stage II disease. The 5-yr overall survival (OS), progression-free survival (PFS), and local control rates for all patients were 84.4%, 63.6%, and 90.8%, respectively. The 5-yr OS and PFS rates were 95.0% and 77.4% for Ann Arbor stage I disease, and 75.1% and 51.7% for stage II disease, respectively. Lymph node involvement was the main pattern of disease progression or relapse for these patients. Adult patients with early stage systemic ALCL treated with doxorubicin-based chemotherapy and radiotherapy had a favorable prognosis., (© 2013 John Wiley & Sons A/S.)
- Published
- 2013
- Full Text
- View/download PDF